Logo image of PHIL.MI

PHILOGEN SPA (PHIL.MI) Stock Fundamental Analysis

BIT:PHIL - Euronext Milan - IT0005373789 - Common Stock - Currency: EUR

22.5  +0.1 (+0.45%)

Fundamental Rating

7

PHIL gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. While PHIL has a great health rating, its profitability is only average at the moment. PHIL is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes PHIL very considerable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

PHIL had positive earnings in the past year.
PHIL had a positive operating cash flow in the past year.
PHIL had negative earnings in 4 of the past 5 years.
PHIL had negative operating cash flow in 4 of the past 5 years.
PHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFPHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

PHIL has a better Return On Assets (26.89%) than 97.18% of its industry peers.
PHIL's Return On Equity of 32.66% is amongst the best of the industry. PHIL outperforms 95.77% of its industry peers.
PHIL has a Return On Invested Capital of 18.64%. This is amongst the best in the industry. PHIL outperforms 92.96% of its industry peers.
Industry RankSector Rank
ROA 26.89%
ROE 32.66%
ROIC 18.64%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
PHIL.MI Yearly ROA, ROE, ROICPHIL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

The Profit Margin of PHIL (61.21%) is better than 98.59% of its industry peers.
In the last couple of years the Profit Margin of PHIL has grown nicely.
PHIL has a Operating Margin of 50.99%. This is amongst the best in the industry. PHIL outperforms 97.18% of its industry peers.
Looking at the Gross Margin, with a value of 78.83%, PHIL is in the better half of the industry, outperforming 78.87% of the companies in the same industry.
In the last couple of years the Gross Margin of PHIL has grown nicely.
Industry RankSector Rank
OM 50.99%
PM (TTM) 61.21%
GM 78.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
PHIL.MI Yearly Profit, Operating, Gross MarginsPHIL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

9

2. Health

2.1 Basic Checks

PHIL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
PHIL has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for PHIL has been reduced compared to 5 years ago.
PHIL has a better debt/assets ratio than last year.
PHIL.MI Yearly Shares OutstandingPHIL.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PHIL.MI Yearly Total Debt VS Total AssetsPHIL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 15.61 indicates that PHIL is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 15.61, PHIL belongs to the top of the industry, outperforming 95.77% of the companies in the same industry.
The Debt to FCF ratio of PHIL is 0.30, which is an excellent value as it means it would take PHIL, only 0.30 years of fcf income to pay off all of its debts.
PHIL has a better Debt to FCF ratio (0.30) than 100.00% of its industry peers.
PHIL has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
PHIL's Debt to Equity ratio of 0.08 is fine compared to the rest of the industry. PHIL outperforms 71.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.3
Altman-Z 15.61
ROIC/WACC2.21
WACC8.43%
PHIL.MI Yearly LT Debt VS Equity VS FCFPHIL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

PHIL has a Current Ratio of 7.95. This indicates that PHIL is financially healthy and has no problem in meeting its short term obligations.
PHIL has a Current ratio of 7.95. This is amongst the best in the industry. PHIL outperforms 92.96% of its industry peers.
PHIL has a Quick Ratio of 7.76. This indicates that PHIL is financially healthy and has no problem in meeting its short term obligations.
PHIL's Quick ratio of 7.76 is amongst the best of the industry. PHIL outperforms 92.96% of its industry peers.
Industry RankSector Rank
Current Ratio 7.95
Quick Ratio 7.76
PHIL.MI Yearly Current Assets VS Current LiabilitesPHIL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

8

3. Growth

3.1 Past

PHIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 824.63%, which is quite impressive.
PHIL shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 100.72% yearly.
The Revenue has grown by 219.91% in the past year. This is a very strong growth!
Measured over the past years, PHIL shows a very strong growth in Revenue. The Revenue has been growing by 42.46% on average per year.
EPS 1Y (TTM)824.63%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%537.39%
Revenue 1Y (TTM)219.91%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%4764.92%

3.2 Future

The Earnings Per Share is expected to decrease by -3.40% on average over the next years.
The Revenue is expected to grow by 22.55% on average over the next years. This is a very strong growth
EPS Next Y-112.82%
EPS Next 2Y-52.17%
EPS Next 3Y-57.59%
EPS Next 5Y-3.4%
Revenue Next Year-2.6%
Revenue Next 2Y-17.15%
Revenue Next 3Y-14.59%
Revenue Next 5Y22.55%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PHIL.MI Yearly Revenue VS EstimatesPHIL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
PHIL.MI Yearly EPS VS EstimatesPHIL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 20.09, PHIL is valued on the expensive side.
PHIL's Price/Earnings ratio is rather cheap when compared to the industry. PHIL is cheaper than 83.10% of the companies in the same industry.
PHIL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.03.
The Forward Price/Earnings Ratio is negative for PHIL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 20.09
Fwd PE N/A
PHIL.MI Price Earnings VS Forward Price EarningsPHIL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

83.10% of the companies in the same industry are more expensive than PHIL, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, PHIL is valued cheaper than 84.51% of the companies in the same industry.
Industry RankSector Rank
P/FCF 17.12
EV/EBITDA 11.35
PHIL.MI Per share dataPHIL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

PHIL has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as PHIL's earnings are expected to decrease with -57.59% in the coming years.
PEG (NY)N/A
PEG (5Y)0.2
EPS Next 2Y-52.17%
EPS Next 3Y-57.59%

More info and screens

0

5. Dividend

5.1 Amount

PHIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHILOGEN SPA

BIT:PHIL (5/21/2025, 7:00:00 PM)

22.5

+0.1 (+0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)06-28 2025-06-28
Inst Owners8.01%
Inst Owner ChangeN/A
Ins Owners33.71%
Ins Owner ChangeN/A
Market Cap657.90M
Analysts82.5
Price Target27.54 (22.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)12.5%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)701.97%
Revenue NY rev (3m)701.97%
Valuation
Industry RankSector Rank
PE 20.09
Fwd PE N/A
P/S 8.89
P/FCF 17.12
P/OCF 16.11
P/B 4.74
P/tB 4.78
EV/EBITDA 11.35
EPS(TTM)1.12
EY4.98%
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)1.31
FCFY5.84%
OCF(TTM)1.4
OCFY6.21%
SpS2.53
BVpS4.74
TBVpS4.7
PEG (NY)N/A
PEG (5Y)0.2
Profitability
Industry RankSector Rank
ROA 26.89%
ROE 32.66%
ROCE 24.85%
ROIC 18.64%
ROICexc 74.3%
ROICexgc 76.64%
OM 50.99%
PM (TTM) 61.21%
GM 78.83%
FCFM 51.94%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
F-Score8
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.3
Debt/EBITDA 0.25
Cap/Depr 62.05%
Cap/Sales 3.26%
Interest Coverage 56.74
Cash Conversion 98.14%
Profit Quality 84.85%
Current Ratio 7.95
Quick Ratio 7.76
Altman-Z 15.61
F-Score8
WACC8.43%
ROIC/WACC2.21
Cap/Depr(3y)124.83%
Cap/Depr(5y)196.93%
Cap/Sales(3y)15.46%
Cap/Sales(5y)79.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)824.63%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%537.39%
EPS Next Y-112.82%
EPS Next 2Y-52.17%
EPS Next 3Y-57.59%
EPS Next 5Y-3.4%
Revenue 1Y (TTM)219.91%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%4764.92%
Revenue Next Year-2.6%
Revenue Next 2Y-17.15%
Revenue Next 3Y-14.59%
Revenue Next 5Y22.55%
EBIT growth 1Y526.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-110.34%
EBIT Next 3Y-54.15%
EBIT Next 5YN/A
FCF growth 1Y459.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y946.64%
OCF growth 3YN/A
OCF growth 5Y135.99%